In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.

In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.

In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.

In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.

In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.

In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.

Selection of Bruton’s tyrosine kinase (BTK) inhibitor therapy in CLL patients requires recognizing key differences between first- and next-generation agents in terms of the safety profile and efficacy across all patient types, including patients with high-risk features. Newer BTK inhibitors with greater kinase selectivity have shown fewer off-target adverse effects and allowed patients to switch BTK inhibitors with continued clinical benefit, fewer recurrences, and lower severity.

Selection of Bruton’s tyrosine kinase (BTK) inhibitor therapy in CLL patients requires recognizing key differences between first- and next-generation agents in terms of the safety profile and efficacy across all patient types, including patients with high-risk features. Newer BTK inhibitors with greater kinase selectivity have shown fewer off-target adverse effects and allowed patients to switch BTK inhibitors with continued clinical benefit, fewer recurrences, and lower severity.

Selection of Bruton’s tyrosine kinase (BTK) inhibitor therapy in CLL patients requires recognizing key differences between first- and next-generation agents in terms of the safety profile and efficacy across all patient types, including patients with high-risk features. Newer BTK inhibitors with greater kinase selectivity have shown fewer off-target adverse effects and allowed patients to switch BTK inhibitors with continued clinical benefit, fewer recurrences, and lower severity.

Struggling to manage ATTR-CM? Our faculty are exploring the key considerations shaping current clinical trial design and how innovations might change our approach to the management of ATTR-CM in the future. They'll also discuss the use of outpatient diuretic intensification as a potential endpoint in trials and the ongoing challenge of defining and measuring “clinically meaningful benefit” for patients with ATTR-CM. Don't miss this opportunity to gain valuable insights and elevate your understanding of ATTR-CM treatment strategies!